Completed
NCT Number: NCT01028443
Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes
The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Ophthalmic Research Center, Tehran, Tehran Province, Iran
Loading trial locations.
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Penetrating keratoplasty in eyes without vascularization
Exclusion criteria
- History of previous intraocular surgery
Treatment and study plan
Artelose
DrugPrimary outcomes
-
The rate of rejection after drop sessation
Time frame: 3 years
Sponsors and collaborators
Lead sponsor
Shahid Beheshti University of Medical Sciences
Other
Registry information
Important dates
- First posted
- Dec 9, 2009
- Registry last updated
- Dec 9, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.